Glenmark Pharma Q4 PAT may dip 27.7% YoY to Rs. 173.7 cr: Edelweiss



Glenmark Pharma Q4 PAT may dip 27.7% YoY to Rs. 173.7 cr: Edelweiss Net Sales are expected to decrease by 8.5 percent Y-o-Y (up 2 percent Q-o-Q) to Rs. 2,247.6 crore, according to Edelweiss.

Leave a Reply

Your email address will not be published. Required fields are marked *